Swedish Orphan Biovitrum AB/ SE0000872095 /
13/09/2024 17:29:40 | Chg. +5.80 | Volume | Bid17:29:40 | Ask17:29:40 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
326.80SEK | +1.81% | 249,500 Turnover: 72.6 mill. |
327.20Bid Size: 362 | 327.40Ask Size: 49 | 115.8 bill.SEK | - | 43.75 |
GlobeNewswire
08/08
Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
30/07
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
GlobeNewswire
24/05
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Act...
GlobeNewswire
15/05
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at ...
GlobeNewswire
09/05
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
06/05
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
06/05
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLON...
GlobeNewswire
01/05
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on...
GlobeNewswire
04/04
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination wit...
GlobeNewswire
03/04
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
GlobeNewswire
13/03
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business U...
GlobeNewswire
06/03
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
GlobeNewswire
06/03
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March...